PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology
+$0.04 today
- Market cap
- $65.06M
- Beta
- 1.36
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$1.47
Volume 0.43M
Average 0.38M
PMVP Net Income
Bottom-line profit after all expenses, interest, and taxes.
PMV Pharmaceuticals, Inc.NASDAQ: PMVP
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$18.04M, compared with -$17.44M a year earlier. Trailing-twelve-month net income was -$78.34M.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$76.89M (+1.1%) for the fiscal year ending Dec 2026, a step up from the -32.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.04M-0.0% QoQ
- Last fiscal yearDec 2025
- -$77.74M-32.4% YoY
- LTMMar 2026
- -$78.34M-28.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -3.5% | -0.6% | +2.9 pp |
| 1 year | -32.4% | +1.1% | +33.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (77.74M) USD
- Year-over-year change
- -32.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (77.74M) | -32.4% |
| FY2024 | 2024-12-31 | (58.71M) | +14.9% |
| FY2023 | 2023-12-31 | (68.96M) | +5.9% |
| FY2022 | 2022-12-31 | (73.32M) | -26.7% |
| FY2021 | 2021-12-31 | (57.85M) | — |
Net Income vs competitors
How PMVP compares with its peers on the latest reported figures
- PMVP's LTM Mar 2026 net income of -$78.34M is the 6th highest of the 9 companies compared; the peer median is -$73.65M.
- Its year-over-year change of -28.7% is the lowest of 9, against a peer median of +15.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $37.1M | +163.8% | — | 14.5% | |
| LTM Mar 2026 | -$44.95M | +65.1% | — | — | |
| LTM Mar 2026 | -$58.88M | +22.2% | — | — | |
| LTM Mar 2026 | -$70.03M | -10.4% | — | 36857.4% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$77.27M | +7.7% | — | — |
| LTM Mar 2026 | -$78.34M | -28.7% | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | -$101.42M | +63.1% | — | 2366.3% |
| LTM Mar 2026 | -$104.29M | -8.2% | — | — | |
| LTM Mar 2026 | -$124.31M | +5.5% | — | 1360.6% | |
| Peer median (excluding PMVP) | -$73.65M | +15.0% | — | 1863.5% | |
Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.28M | 650K | 1.26M | 1.14M | 0 |
| Gross Profit | (1.28M) | (650K) | (1.26M) | (1.14M) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 36.19M | 51.67M | 54.63M | 57.38M | 69.88M |
| Selling, General & Admin | 20.83M | 24.72M | 24.25M | 26.92M | 16.33M |
| Operating Expenses | 57.01M | 76.39M | 78.88M | 84.3M | 86.21M |
| Depreciation & Amortization | 1.28M | 650K | 1.26M | 1.14M | 133K |
| EBITDA | (56.54M) | (72.68M) | (67.7M) | (73.67M) | (79.78M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (58.29M) | (77.04M) | (80.13M) | (85.45M) | (86.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 449K | 3.63M | 11.17M | 10.66M | 6.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 470K | 3.71M | 11.17M | 10.64M | 6.29M |
| Income Before Tax | (57.82M) | (73.33M) | (68.96M) | (74.81M) | (79.91M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 23K | (9K) | 2K | (16.1M) | (2.17M) |
| Net Income | (57.85M) | (73.32M) | (68.96M) | (58.71M) | (77.74M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.28) | (1.61) | (1.44) | (1.14) | (1.48) |
| EPS (Diluted) | (1.28) | (1.61) | (1.44) | (1.14) | (1.48) |
| Weighted Avg Shares | 45.14M | 45.59M | 48.01M | 51.58M | 52.54M |
| Weighted Avg Shares (Diluted) | 45.14M | 45.59M | 48.01M | 51.58M | 52.54M |
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
Intrinsic Alpha fair value
Locked
Current Price
$1.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.